Holen Sie sich die Stockscreener-App
4.67
1.52%
0.07
Handel nachbörslich:
4.74
0.07
+1.50%
Opus Genetics Inc Aktie (IRD) Neueste Nachrichten
Balyasny Asset Management L.P. Expands Opus Genetics Inc (IRD) S - GuruFocus
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Opus Genetics stock maintains buy rating ahead of trial data By Investing.com - Investing.com Canada
Citizens reiterates Opus Genetics stock rating ahead of trial data - Investing.com
Citizens reiterates Opus Genetics stock rating ahead of trial data By Investing.com - Investing.com India
Wall Street Zen Upgrades Opus Genetics (NASDAQ:IRD) to "Hold" - MarketBeat
IRD Q2 2026 Earnings: Narrower-than-Expected Loss of -$0.14 Beats Estimates, Though Shares Slip 2.96%Profitability Analysis - vinanet.vn
Opus Genetics (NASDAQ:IRD) Rating Increased to Hold at Zacks Research - MarketBeat
Opus Genetics Q3 EPS Lifted by Brookline Capital Markets - MarketBeat
Brokers Set Expectations for Opus Genetics FY2030 Earnings - MarketBeat
Opus Genetics FY2026 EPS Estimate Boosted by HC Wainwright - MarketBeat
Opus Genetics, Inc. (NASDAQ:IRD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How FDA Alignment Is Shaping Opus Genetics' OPGx-LCA5 Development Strategy - Clinical Leader
Opus Genetics completes phase 3 enrollment for OPGx-LCA5 gene therapy - Glance by Eyes On Eyecare
Opus Genetics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Opus Genetics Inc (IRD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Opus Genetics (IRD) Gets a Buy from RBC Capital - The Globe and Mail
Piper Sandler Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Is Opus Genetics Inc (IRD) Significantly Overvalued After Q2 Ear - GuruFocus
Opus Genetics (IRD) Q1 2026 Earnings: Deep EPS Miss Heightens Scrutiny on Clinical-Stage SpendingRevenue Beat Analysis - vinanet.vn
OPUS GENETICSMAY OFFER AND SELL UP TO $300 MLN OF SECURITIESSEC FILING - Moomoo
Opus Genetics (NASDAQ:IRD) Upgraded at Wall Street Zen - MarketBeat
IRD Maintained by RBC Capital -- Price Target Lowered to $9.00 - GuruFocus
A. G. P. Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $9 - Moomoo
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $9 to $10 - Moomoo
Opus GeneticsMay Offer And Sell Up To $300 Million Of SecuritiesSEC Filing - TradingView
RBC Adjusts PT on Opus Genetics to $9 From $10, Maintains Outperform Speculative Risk Rating - marketscreener.com
Opus Genetics (NASDAQ: IRD) sets $300M shelf and $125M ATM stock plan - Stock Titan
Opus Genetics earnings beat by $0.02, revenue fell short of estimates - Investing.com Canada
Opus Genetics (NASDAQ:IRD) Releases Earnings Results - MarketBeat
Opus Genetics, Inc. 2Q 2026: Revenue $0.8M, EPS $(0.14) — 10-Q Summary - TradingView
Opus Genetics (Nasdaq: IRD) hit by $73.6M loss, rising warrant costs - Stock Titan
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update - The Manila Times
Opus Genetics Q2 revenue falls and misses estimates - TradingView
IRD: Gene therapy pipeline advances with strong cash position and key clinical milestones ahead - TradingView
Opus Genetics Reports Q2 2026 Results and Advances Multiple IRD Gene Therapy Programs with OPGx-BEST1 Data Expected in September - Quiver Quantitative
Opus Genetics reports Q2 2026 results: $0.8M revenue, $8.1M net loss, $88.8M cash - TradingView
Opus Genetics Completes Phase 3 Enrollment for AAV Gene Therapy OPGx-LCA5 - BioPharm International
Opus Genetics (IRD) to Release Quarterly Earnings on Wednesday - MarketBeat
BTIG Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Opus Genetics completes enrollment in LCA5 gene therapy trial - Investing.com
Opus Genetics completes enrollment in LCA5 gene therapy trial By Investing.com - Investing.com South Africa
Opus Genetics Completes Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 For LCA5-Associated Inherited Retinal Disease - marketscreener.com
Opus Genetics, Inc. $IRD Shares Sold by Perceptive Advisors LLC - MarketBeat
Opus Genetics, Inc. Revenue Breakdown – NASDAQ:IRD - TradingView
Opus Genetics (IRD) Slides 3.4% to $3.71 as Gene Therapy Stock Presses Key SupportIV Contraction - vinanet.vn
Opus Genetics (IRDC) Q1 2026 Earnings: Wide EPS Miss Reflects Pre-Revenue R&D InvestmentPre-Announcement Alert - vinanet.vn
Opus Genetics, Inc. Revenue Breakdown – FWB:R3X1 - TradingView
Form 4 Opus Genetics Inc For: 27 July By Investing.com - Investing.com India
Opus Genetics Inc (IRD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Opus Genetics CFO Robert Gagnon sells $22,941 in company stock - Investing.com
Opus Genetics COO Joseph Schachle sells $13,653 in common stock By Investing.com - Investing.com Canada
Opus Genetics CEO George Magrath sells $27,925 in common stock By Investing.com - Investing.com Canada
Opus Genetics COO Joseph Schachle sells $13,653 in common stock - Investing.com
Opus Genetics CEO George Magrath sells $27,925 in common stock - Investing.com
Opus Genetics President Benjamin Yerxa Executes Automatic Sale of 7,429 Shares to Cover RSU Tax Withholding - Kalkine Media
Opus Genetics, Inc. (IRD) CFO auto-sells shares to cover RSU taxes - Stock Titan
Opus Genetics, Inc. (IRD) COO’s 4,644 shares sold to cover RSU tax withholding - Stock Titan
Opus Genetics (IRD) CEO sells shares to cover RSU-related tax obligations - Stock Titan
IRD|Opus Genetics Inc|Price:3.365|Chg%:+0.285 - TradingKey
Opus Genetics Inc (IRD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Opus Genetics Inc (IRD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):